The continual disruption caused by COVID-19 is starting to have an impact on the drug development programme timings of leading pharma companies;
Sakis Paliouras, PhD, Oncology and Hematology Analyst at GlobalData, a leading data and analytics company, offers his analysis on the increase in delays in ongoing clinical trials:
“According to GlobalData * 432 clinical trials have been delayed, suspended, or otherwise affected over the last 4 days (to 09.04.20) by the disruption of the COVID-19 pandemic an increase of over 70% on the previous figure of * 253 trial delays.
“The greatest proportion of disrupted clinical trials during this period concerned clinical development in oncology which made up ** 28% of the total trials measured on 8th April followed by the central nervous system and gastrointestinal clinical development areas at ** 14% and ** 8% of the total trials measured respectively...
Full text GMPnews.Net